Some research data suggest that therapeutic monitoring may assist in enhancing the effectiveness and reducing adverse events. However, routine monitoring of drug levels in clinical practice is not indicated.

A detailed baseline dementia assessment should be performed prior to initiating galantamine treatment. In addition, after starting therapy, at all follow-up visits, assessments of cognition and behavior should occur to assess therapeutic efficacy and ensure patient safety.